Reversible acute renal failure following single administration of fludarabine
| Autor: | R Nunes, M Nave, Miguel Abecasis, F. Leal da Costa, José Luís Passos-Coelho, Nuno Miranda |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Transplantation
medicine.medical_specialty medicine.diagnostic_test business.industry Purine analogue Context (language use) Hematology medicine.disease Gastroenterology Nephrotoxicity Fludarabine Tumor lysis syndrome Internal medicine Immunology Medicine Renal biopsy business Kidney disease medicine.drug |
| Zdroj: | Bone Marrow Transplantation. 33:671-671 |
| ISSN: | 1476-5365 0268-3369 |
| DOI: | 10.1038/sj.bmt.1704404 |
| Popis: | Fludarabine is a purine analogue with high activity in lymphoid malignancies and a frequent component of reduced-intensity conditioning regimens, due to its immunosuppressive properties. Renal toxicity of fludarabine occurs in less than 5% of patients,1 usually in the context of tumor lysis syndrome.2 In one case report of fludarabine-associated nephrotoxicity occurring after the administration of a cumulative dose of 500 mg/m2 of fludarabine, renal biopsy showed the presence of mesangiocapillary glomerulonephritis.3 Another report described the occurrence of crescentic glomerulonephritis, with p-ANCA positivity, after three courses of treatment with this drug.4 We report a case of acute renal failure developing after the first administration of fludarabine, without associated tumor lysis syndrome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|